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costs and/or health-related quality of life. The following complications were se-
lected: cardiovascular disease, peripheral neuropathy, renal disease, retinopathy,
cataract, hypoglycemia, ketoacidosis and adverse birth outcomes. CONCLUSIONS:
Since 2003, 281 reports of 72 studies (including many large, observational studies)
have been published. These reports have substantially increased the available ev-
idence describing complications in T1DM patients. The DCCT/EDIC studies
uniquely provide long-term follow-up (now more than 23 years) of patients man-
aged using strategies that are reasonably representative of contemporary T1DM
management.
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OBJECTIVES: To evaluate the safety of preoperative vitamin D replacement in mild
primary hyperparathyroidism. METHODS: Data were searched from Medline, EM-
BASE, Cochrane CENTRAL and abstracts form annual scientific meetings of various
international bone and mineral societies. Studies examining the effect of preoper-
ative vitamin D replacement in patients with mild primary hyperparathyroidism
(serum calcium 12 mg/dl), irrespective of year and language of the publication
were included in the present meta-analysis. Data were extracted from text of the
included publications or abstract of conferences. RESULTS: The pooled mean dif-
ference for serum calcium, phosphate, intact parathyroid hormone levels and uri-
nary calcium excretion before and after vitamin D replacement in mild primary
hyperparathyroidism were 0.06 mg/dl (95% CI, -0.11, 0.23, Z  0.71, P  0.48), -0.01
mg/dl (95% CI, -0.14, 0.13, Z  0.12, P  0.91), 17.18 pg/ml (95% CI, 1.26, 33.11, Z 
2.11, P  0.03), -56.95 mg/24hr (-104.28, -9.62, Z  2.36, P  0.02) ) respectively.
CONCLUSIONS: Preoperative vitamin D replacement in subjects with mild primary
hyperparathyroidism and vitamin D deficiency is safe. This meta-analysis sup-
ports the recommendation on replacement of vitamin D in subjects with primary
hyperparathyroidism and vitamin D deficiency by Third international workshop on
diagnosis of asymptomatic primary hyperparathyroidism.
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OBJECTIVES: Pasireotide is a novel, injectable multireceptor-targeted somatostatin
analogue that binds with high affinity to four of the five somatostatin receptors. It
has been commercially available in Europe since May 2012 and is the first pituitary-
targeted medical therapy indicated for adult patients with Cushing’s disease (CD)
for whom surgery has failed or is not an option. This analysis aims to quantify the
budget impact (BI) of utilizing pasireotide as second-line therapy in CD in Germany.
METHODS: A thorough chart audit was conducted to analyze resource utilization
and market shares of standard of care in CD. Epidemiology, treatment response
complications and adverse event (AE) data were derived from published literature.
Pasireotide data were taken from a Phase III clinical trial. German tariffs for each
resource were then applied to an Excel-based model to compare utilization and
costs with and without the introduction of pasireotide (net BI) for patients with CD
over a 5-year horizon from the German health care system. RESULTS: Applying a
CD prevalence rate of 39 per million and the treatment success of first-line therapy,
fewer than 200 patients with CD are eligible for pasireotide treatment in Germany.
Assuming that pasireotide in years 1–5 will have a market share of 8%, 15%, 23%,
25% and 26%, the net BI is 812,769€, 549,676€, 1,553,976€, 2,088,511€ and 2,209,948€,
respectively. Budget impact is reduced by early identification of pasireotide non-
responders, low cost of treating pasireotide AEs, and potential displacement of
second-line surgical treatments such as bilateral adrenalectomy. Pasireotide BI
may be further minimized if offsets due to lower consumption of health care re-
sources in controlled patients are considered. CONCLUSIONS: The introduction of
pasireotide into the German health care system will result in clinical benefits for
CD patients associated with a limited and predictable BI.
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OBJECTIVES: Linagliptin is a new oral hypoglycaemiant agent (OHA) from the class
of dipeptidyl peptidase 4 (DPP-4) inhibitors, mostly excreted by biliary pathway,
that has no contra-indication in renal impaired patients. Linagliptin in indicated
for dual therapy (add on to metformin) and for triple therapy (add on to metformin
and Sulfamides).”. The aim of this study is to estimate the potential budget impact
of linagliptin (either as mono substance or in combination with metformin) from
most current DPP-4 inhibitor prescribing patterns. METHODS: A budget impact
model was developed from a French payer perspective. The model focused on
drugs and insulin administration costs. Three prescription patterns were consid-
ered for linagliptin treatment initiation: substitution without treatment intensifi-
cation, substitution with treatment intensification and initiation in naïve patients.
Treatment initiation data were obtained via retrospective analysis of 2011 prescrib-
ing data from the Thales database. DPP-4 inhibitors latest entrants (saxagliptin/
vildagliptin-metformin combinations) were used as benchmark for linagliptin. For
analysis purpose, the daily cost of linagliptin was assumed at market average
(1.19€/day exfactory). RESULTS: Considering a virtual cohort of 10,000 patients
treated with linagliptin (mono or combination with metformin), the whole treat-
ment cost over 5 years would be 21,717 k€ compared with 18,996 k€ for a cohort of
the same size treated with current alternatives. Benefits were observed among
patients receiving triple therapy mainly because of competition with substitution
of more expensive drugs such as GLP1 analogues and insulins. Sensitivity analysis
showed that deploying the “add on to insulin indication” could reduce the budget
impact up to 8 %. CONCLUSIONS: The estimated budget impact of linagliptin will
be close to neutrality, as around 87.5 % of linagliptin costs are already offset by
substitutions, based on conservative assumptions.
PDB23
ECONOMIC IMPACT OF ANALOGUE INSULIN ON HEALTH EXPENDITURE AT THE
MEXICAN INSTITUTE OF SOCIAL SECURITY IN 2012. AN EXPENDITURE
REDUCTION PROPOSAL
Panopoulou P, Garcia-Contreras F, Paladio-Hernandez JA, Huerta JL, Gonzalez Pier E
Mexican Institute of Social Security, Mexico City, DF, Mexico
OBJECTIVES: To measure the economic impact of insulin analogues, and its partial
substitution by human insulin on the Mexican Institute of Social Security (IMSS)
health expenditure METHODS: Considering similar efficacy in both types of insu-
lin, a retrospective analysis on the supply department of the Administrative Direc-
torate database, at the IMSS, was conducted. The consumed volume during 2011
was identified; all types of insulin included in the IMSS formulary were incorpo-
rated to the analysis. The information gathered was stratified by analogue and
human insulin. The share in volume and monetary values was established for all
insulin at the institutional market. The information was traspolated to 2012 prices.
The impact on the expenditure was analyzed when analogue insulin was substi-
tuted by human insulin in 25 and 50%. Potential savings for the IMSS were obtained
if analogue insulin consumption is reduced by substituting it with human insulin.
An exchange rate of 14 MXN to 1 USD updated to May the 30, 2012 was considered
RESULTS: The IMSS total expense in insulin in 2011 reached $41,281,671.26 USD,
76.3% was expend on analogue insulin whilst it only represented 19.3% of all insu-
lin purchased in 2011. The information transpolated to 2012 prices, showed
$43,208,169.84 USD or an increase by 4.6% in expenditure considering the same
institutional insulin market share. Substituting 25% of the volume of analogue
insulin with human insulin may lead to savings in $7,971,446.06 USD equivalent to
18.4% of the expected expenditure for 2012, meanwhile substituting 50% of the
volume of analogue insulin with human insulin leads to potentials savings by
$15,942,892.11 USD, equivalent to 36.9% of the expected expenditure for 2012
CONCLUSIONS: Substituting analogue insulin by human insulin in 50% is associ-
ated to a drop in 36.9% in the total insulin expenditure at the IMSS not affecting
health outcomes in diabetic patients
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OBJECTIVES: To compare health care resources utilization and corresponding
costs in adults patients with painful Diabetes Peripheral Neuropathy (pDPN) who
initiated treatment with pregabalin or gabapentin as an add-on therapy to usual
care in Spanish daily medical practice setting.METHODS:A retrospective database
study was designed including systematically all medical records of adult patients,
with pDPN (ICD-9-CM codes; 250.6-357.2), both gender, who were covered by the
BSA health plan in years 2006-2009, and that initiated treatment with pregabalin or
gabapentin as an add-on therapy for the first time. Socio-demographics, co-mor-
bidity burden index, treatment duration, all type health care resources and days
off-work due to pDPN were assessed. Societal perspective was applied in estimat-
ing costs. Comparisons of costs were adjusted by age, sex and the Charlson index of
co-morbidity. RESULTS: A total of 395 medical records were eligible for analysis:
227 (57.5%) with pregabalin and 168 (42.5%) with gabapentin. No significant differ-
ences were observed in previous exposition to analgesics: pregabalin 2.7 (1.9) drugs;
gabapentin 2.6 (1.9), p0.05. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.9 (2.2) vs. 3.1 (2.1); p0.05, mainly due to a higher utilization of
non-narcotics (78.0% vs. 71.8%; p0.05) and opioids (32.7% vs. 28.6%; p0.05).
Health care costs accounted for the 59.2% of total cost, with a mean cost per patient
of €2,476. Adjusted mean (95% CI) total costs were significantly lower in patients
receiving pregabalin [€2,003 (1,427-2,579)] compared with those treated with gaba-
pentin [€3,127 (2,463-3,790)], p0.013, mainly due to lower health care costs; €1,312
(1,192-1,432) versus €1,675 (1,537-1,814), respectively (p0.001). Less use of con-
comitant analgesics, medical visits and days off-work accounted for such findings.
CONCLUSIONS: Treatment of pDPN patients with pregabalin add-on to usual care
could be a cost-saving alternative from the societal perspective when compared
with gabapentin in real world settings in Spain.
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